Price
No data yet.
Social Signal Score
Revenue
$119.22MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Krish S. Krishnan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 295
- Beta
- 0.54
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 48.09
Financials
Revenue
$119.22M+93775.6%Net Income
$54.77MEBITDA
$66.08MFree Cash Flow
$71.22MEPS (diluted)
$1.79Shares Outstanding (diluted)
30.66M+617.0%Operating Expenses
$54.37MCash & Debt
$845.63MReturn of Capital
$108.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $389.13M | $204.83M | $7.08 |
| 2024 | $290.51M | $89.16M | $3.12 |
| 2023 | $50.70M | $10.93M | $0.40 |
| 2022 | $0.00 | $-139.97M | $-5.49 |
| 2021 | $0.00 | $-69.57M | $-3.13 |
| 2020 | $0.00 | $-32.17M | $-1.71 |
| 2019 | $0.00 | $-19.09M | $-1.20 |
| 2018 | $1.03M | $-10.89M | $-0.97 |
| 2017 | $0.00 | $-7.92M | $-1.48 |
| 2016 | $0.00 | $-1.15M | $-0.27 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $10.40
- Implied price
- $363.94
- Return from $369.76
- -0.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $180.94 — -51.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| -2.0% | -15.4% | -12.3% | -9.5% | -7.1% | -4.9% |
| 3.0% | -11.1% | -7.8% | -4.9% | -2.4% | -0.0% |
| 8.0% | -6.8% | -3.3% | -0.3% | 2.4% | 4.8% |
| 13.0% | -2.5% | 1.1% | 4.3% | 7.1% | 9.7% |
| 18.0% | 1.8% | 5.6% | 8.9% | 11.9% | 14.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
130+30.00%Social Signal Score
Mentions (2)
- Newszacks.com·5h ago·Positive
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
View source ↗ - Newszacks.com·1d ago·Neutral
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Mon, Nov 2(in 8 weeks)
Consensus estimate $1.91 per share
Typical surprise +17.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$1.79 vs $1.70beat
- Mon, May 4$1.83 vs $1.45beat
- Tue, Feb 17$1.70 vs $1.62beat
- Mon, Nov 3$2.66 vs $1.12beat
- Mon, Aug 4$1.29 vs $1.08beat
- Tue, May 6$1.20 vs $1.38miss
Estimates and results for KRYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KRYS officers and directors.
- Bought
- —
- Sold
- $37.5m
0 trades
53 trades
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
- Rossi Dino Asold
47 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.